MedTrace Logo

Aprepitant to Improve Same Day Discharge for TKA

NCT07639723 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2026-06-10

No results posted yet for this study

Summary

The purpose of this research is to study whether adding an FDA approved medication called aprepitant (a medication given to patients like you to reduce or eliminate nausea and vomiting) to the usual treatment to prevent nausea and vomiting given to patients during knee replacement surgery helps more patients go home on the same day of surgery (before midnight) by eliminating nausea and vomiting.

Conditions

  • PONV

Interventions

DRUG

Aprepitant Injection

32mg aprepitant will be administered intravenously preoperatively during single sided total knee arthroscopy

DRUG

Ondansetron (Zofran)

4 mg IV ondansetron will be given at surgical closure during total knee arthroscopy

DRUG

Dexamethasone

4 mg IV dexamethasone will be given after induction of MAC sedation anesthesia during total knee arthroscopy

OTHER

Placebo

Patients will receive 32 mg of intravenous (IV) placebo preoperatively for a total knee arthroscopy

Sponsors & Collaborators

  • Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.)

    collaborator UNKNOWN

  • Endeavor Health

    lead OTHER

Principal Investigators

  • Steven Greenberg, MD · Endeavor Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2027-07-31
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07639723 on ClinicalTrials.gov